Sumatriptan-naproxen fixed combination for acute treatment of migraine: A critical appraisal

Drug Design, Development and Therapy

Volumn , Issue 4, 2010, Pages 9-17

  Khoury, Chaouki K ^a   Couch, James R ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Migraine; Sumatriptan naproxen; Treatment; Treximetspi_sup spii_sup

Indexed keywords

NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; PLACEBO; SUMATRIPTAN; TREXIMET; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CHEST PRESSURE; CLINICAL TRIAL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; FLUSHING; HEALTH CARE COST; HUMAN; IMMUNOREACTIVITY; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NECK INJURY; NECK PRESSURE; PARESTHESIA; PATIENT SATISFACTION; PHONOPHOBIA; PHOTOPHOBIA; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SKIN TINGLING; TENSION HEADACHE; TERATOGENICITY; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE DISORDERS; NAPROXEN; SUMATRIPTAN;

EID: 77953661115     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s8410     Document Type: Review

References (120)

1. Rasmussen BK. Epidemiology of headache. Cephalalgia. 2001; 21(7):774-777.
2. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998;279(5):381-383.
3. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993;43(6 Supplement 3): S6-S10.
4. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology. 1999;53(3):537-542.
5. Lipton, et al. Headaches and face pain as a manisfestation of Munchausen Syndrome. Headache. 1999;39(1):45-50.
6. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia. 1996;16(4):231-238.
7. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2(1):67-76.
8. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994;28(5):659-664.
9. RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.
10. Rapoport AM. Acute treatment of headache. J Headache Pain. 2006;7(5):355-359. Epub 2006 Oct 27.
11. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J of Neurol. 2009;16(9):968-981.
12. Lexi-Comp Online [homepage on the Internet]. Hudson, OH: Lexi-Comp, Inc.; c2008-09 [cited 2009 Aug 27]. Available from: http://online.lexi.com/crlsql/servlet/crlonline?siteid=721.
13. Roche. EC-Naprosyn® (naproxen) delayed-release tablets, Naprosyn® (naproxen) tablets, Anaprox®/Anaprox® DS (naproxen sodium) tablets, and Naprosyn® (naproxen) suspension prescribing information. Nutley, NJ; 2006.
14. Elan. Naprelan® (naproxen sodium) controlled-release tablets prescribing information (dated 2000 Mar) In: Physician's desk reference. 56th ed. Montvale, NJ: Medical Economics Company, Inc; 2002. p. 1293-1295.
15. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307-314.
16. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644-648.
17. Riendeau D, Charleson S, Cromlish W, et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997;75:1088-1095.
18. DeWitt DL, Bhattacharyya D, Lecomte M, et al. The differential susceptibility of prostaglandin endoperoxide H synthases-1 and -2 to nonsteroidal anti-inflammatory drugs: aspirin derivatives as selective inhibitors. Med Chem Res. 1995;5:325-343.
19. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase - a review. Prostaglandins and Other Lipid Mediators. 1998;56:341-361.
20. LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999;106(Suppl 5B):37S-42S.
21. Ansell BM, Hanna DB, Stoppard M. Naproxen absorption in children. Curr Med Res Opin. 1975;3:46-50.
22. Moran H, Hanna DB, Ansell BM, et al. Naproxen in juvenile chronic polyarthritis. Ann Rheum Dis. 1979;38:152-154.
23. Makela AL. Naproxen in the treatment of juvenile rheumatoid arthritis. Scand J Rheumatol. 1977;6:193-205.
24. Nicholls A, Hazleman B, Todd RM, et al. Long-term evaluation of naproxen suspension in juvenile chronic arthritis. Curr Med Res Opin. 1982;8:204-207.
25. Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis: assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol. 1984;13:342-350.
26. Williams PL, Ansell BM, Bell A, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. Br J Rheumatol. 1986;25:67-71.
27. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia. 1985;5:5-10.
28. Snow V, Weiss K, Wall EM, et al. Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache. Ann Intern Med. 2002;137(10):840-849.
29. DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. St. Paul, MN: American Academy of Neurology; 2001. Available from: http://www.aan.com.
30. Bayer HealthCare. Aleve® (naproxen sodium) tablet labeling. Morristown, NJ; 2006.
31. NM, Silberstein SD, Freitag FG, et al. Evidence-based guide-lines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. St. Paul, MN: American Academy of Neurology; 2001. Available from: http://www.aan.com.
32. Gold, Harriott. Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibers innervating craniofacial tissues. Cephalalgia. 2008;28:933-944.
33. Silberstein SD, Freitag FG, Bigal ME. Migraine treatment. In: Silberstein SD, Lipton RB, Dodick DW, editors. Wolff's headache and other head pain. 8th ed. New York: Oxford University Press; 2008. p. 177-292.
34. McGuigan MA. Ergot Alkaloids. Clin Toxicol Rev. 1984;6:1-2.
35. Hsu VD. Sumatriptan: a new drug for vascular headache. Clin Pharm. 1992;11:919-929.
36. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:538-547.
37. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55(1):27-36.
38. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26.
39. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443-1454.
40. GlaxoSmithKline. Imitrex® (sumatriptan succinate) tablets prescribing information. Research Triangle Park, NC; 2001.
41. GlaxoSmithKline. Imitrex® (sumatriptan succinate) tablets prescribing information. Research Triangle Park, NC; 2006.
42. Lacey LF, Fowler PA. The clinical pharmacology of sumatriptan. Cephalalgia. 1993;13(Suppl 13):156.
43. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
44. Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. 2005 Apr 6 [cited 2009 Aug 27]. Available from: http://www.fda.gov.
45. Sanak M, Pierzchalska M, Bazan-Socha S, et al. Enhanced Expression of the Leukotriene C(4) Synthase Due to Overactive Transcription of an Allelic Variant Associated With Aspirin-Intolerant Asthma. Am J Respir Cell Mol Biol. 2000;23(3):290-296.
46. Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 Synthase Promoter Polymorphism in Japanese Patients With Aspirin-Induced Asthma. J Allergy Clin Immunol. 2002;109(6):936-942.
47. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
48. Steinhubl SR. The use of anti-inflammatory analgesics in the patient with cardiovascular disease: what a pain. J Am Coll Cardiol. 2005;45(8):1302-1303.
49. Food and Drug Administration. New information for healthcare professionals: Concomitant use of ibuprofen and aspirin. 2006 Sep [cited 2009 Aug 27]. Available from: http://www.fda.gov.
50. Food and Drug Administration. Concomitant use of ibuprofen and aspirin: potential for attenuation of the antiplatelet effect of aspirin [science paper]. 2006. Available from: http://www.fda.gov.
51. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295-1301.
52. Food and Drug Administration. Labeling revisions for NSAIDs. FDA Drug Bull. 1989;19:3-4.
53. Merck & Co., Inc. Dolobid® (diflunisal) tablets prescribing information. Whitehouse Station, NJ; 2006 Feb.
54. Glaxo Wellcome. Imitrex® (sumatriptan succinate) injection prescribing information. Research Triangle Park, NC; 2001 Mar.
55. Glaxo Wellcome. Imitrex® (sumatriptan) nasal spray prescribing information. Research Triangle Park, NC; 2001 Mar.
56. GK, editor. AHFS drug information: naproxen. Bethesda, MD: American Society of Health-System Pharmacists; 2003. p. 1986-1992.
57. GlaxoSmithKline. Imitrex® (sumatriptan succinate) injection prescrib-ing information. Research Triangle Park, NC; 2006 Jun.
58. Food and Drug Administration. Combined Use of 5-Hydroxytryptamine Receptor Agonists (Triptans), Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) May Result in Life-threatening Serotonin Syndrome. 2006 Jul 19 [updated 2009 Jul 1; cited 2009 Aug 27]. Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm124349.htm.
59. GlaxoSmithKline. Imitrex® (sumatriptan) nasal spray prescribing information. Research Triangle Park, NC; 2006 Jun.
60. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28:205-214.
61. MedGenMed, Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports. 2007;9(3):48.
62. Shapiro RE, Tepper SJ. The Serotonin Syndrome, Triptans, and the potential for drug-drug interactions. Headache. 2007;47(2): 266-269.
63. Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted? Ann Pharmacother. 2008;42(11):1692-1696. Epub 2008 Oct 28.
64. Lexi-Comp Online [homepage on the Internet]. Hudson, OH: Lexi-Comp, Inc.; c2008-09 [cited 2009 Jul 28]. Available from: http://online.lexi.com.webproxy.ouhsc.edu/crlsql/servlet/crlonline?a=doc&bi=3&id=3725.
65. Block JH, Brackett CC, Singh H. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856-870.
66. CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clinic North Am. 2004;24(3):477-490, vii.
67. Baeza ML, De Barrio M, Herro T, Tornero. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermititis. 2004;51(2):57-62.
68. Couch JR, Lenaerts ME. Medication overuse headache. Minerva Med. 2007;98:221-231.
69. Young WB, Mannix L, Adelman JU, et al. Cardiac risk factors and the use of triptans: a survey study. Headache. 2000;40:587-591.
70. Dodick D, Lipton RB, Martin V, et al; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414-425.
71. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633-1644.
72. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006;332:1302-1305.
73. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk; the seduction of common sense. JAMA. 2006;296:1653-1656.
74. R, Helfand M, Peterson K, et al.; for the Oregon evidence-based practice center under contract no. 290-02-0024. Comparative effective-ness and safety of analgesics for osteoarthritis. Comparative effective-ness review no. 4. Rockville, MD: Agency for Healthcare Research and Quality. 2006 Sep. Available from: http://www.effectivehealthcare.ahrq.gov/synthesize/reports/final.cfm.
75. Fox AW, Spierings EL. Sumatriptan and pregnancy outcome. Headache. 2000;40(10):860-861.
76. Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs. 2003;17(1):1-7.
77. American Academy of Pediatrics Committee on Drugs. The Trans-fer of Drugs and Other Chemicals Into Human Milk. Pediatrics. 2001;108(3):776-789.
78. GlaxoSmithKline. Treximet™ (sumatriptan and naproxen sodium) tab-lets prescribing information. Research Triangle Park, NC; 2008 Aug.
79. Kauffmann RE, Bolliger RO, Wan SH, et al. Pharmacokinetics and metabolism of naproxen in children. Dev Pharmacol Ther. 1982;5: 143-150.
80. Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995;25:464-469.
81. Bateman DN. Sumatriptan. Lancet. 1993;341:221-224.
82. Busch MA, Plachetka JR, Donn KH. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR43175 administered to healthy male volunteers. Cephalalgia. 1989;9(Suppl 10): 414-415.
83. Cady RK, Dexter J, Sargent JD, et al. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology. 1993;43: 1363-1368.
84. Cady RK, Rubino J, Crummett D, et al. Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med. 1994;3:766-772.
85. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
86. Cutler NR, Hussey EK, Sramek JJ, et al. Pharmacokinetics (PK) of oral sumatriptan in migraine patients during an attack and while pain free. Biol Psych. 1992;31:180A.
87. Dixon CM, Saynor DA, Andrew PD, et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metabol Disp. 1993;21:761-769.
88. Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand. 1993;88:63-69.
89. Ferrari MD and the Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
90. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993;14:129-133.
91. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics, and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
92. Fowler PA, Thomas M, Lacey LF, et al. Early studies with the novel 5-HT1-like agonist GR43175 in healthy volunteers. Cephalalgia. 1989;9(Suppl 9):57-62.
93. Gutterman DL, Plachetka JR, Donn K, et al. Evaluation of the safety and pharmacokinetic properties of single subcutaneous doses of GR43175C in healthy, adult, male volunteers. Cephalalgia. 1989; 9(Suppl 10):412-413.
94. Hardebo JE. Subcutaneous sumatriptan in cluster headache: a time study of the effect on pain and autonomic symptoms. Headache. 1993;33:18-21.
95. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol. 1995;47: 543-548.
96. Posner JB. Disorders of sensation: headache and other pain. In: Wyngaarden JB, Smith LH Jr, Bennett JC, editors. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders Company; 1992. p. 2116-2124.
97. Rederich G, Rapoport A, Cutler N, et al. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology. 1995;45(Suppl 7):S15-S20.
98. Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol. 1994;241:463-469.
99. Scott AK. Sumatriptan: clinical pharmacokinetics. Clin Pharmacokinet. 1994;27:337-344.
100. Tansey MJB, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci. 1993;114:109-116.
101. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:332-338.
102. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:306-313.
103. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med. 1991;325:322-326.
104. Warner PE, Brouwer KLR, Hussey EK, et al. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm Res. 1995;12:138-143.
105. Anon. Sumatriptan: a new approach to migraine. Drug Ther Bull. 1992;30:85-87.
106. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol. 1994;47:1253-1257.
107. Fullerton T, Gengo FM. Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother. 1992;26:800-808.
108. Tfelt-Hansen P, Brand J, Dano P, et al. Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia. 1989;9(Suppl 9):73-77.
109. Anon. Sumatriptan for migraine. Med Lett Drugs Ther. 1992;34: 91-93.
110. Ferrari MD, Saxena PRS. Clinical effects and mechanism of action of sumatriptan in migraine. Clin Neurol Neurosurg. 1992;94(Suppl): S73-S77.
111. Russell MB, Holm-Thomsen OE, Nielsen MR, et al. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia. 1994;14:291-296.
112. Silberstein SD, Stark S, DeRossett SE, et al. Superior clinical benefits of a new single-tablet formulation of sumatriptan for-mulated with RT technology and naproxen sodium. Neurology. 2006;66(Suppl 2):A254.
113. Lipton RB, Dodick DW, Adelman JU, et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009;29(2):188-193. Epub 2008 Sep 24.
114. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49(7):971-982. Epub 2009 May 27.
115. Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71(2):114-121. Erratum in: Neurology. 2009;72(15):1369. Toso, Cynthia [added].
116. Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol. 2009;114(1): 106-113.
117. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668-1675.
118. Lockwood AH. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;72(15): 1368-1379.
119. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK. Predictors of adherence to triptans: factors of sustained vs. lapsed users. Headache. 2009;49(3):386-394. Epub 2009 Feb 11.
120. Smith T, Blumenthal H, Diamond M, et al. Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache. 2007;47(2):189-198.